BCTXW | BriaCell Therapeutics Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1000 - 0.1209
52 Week Range	0.1000 - 0.1209
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	12,609
Average Volume	100,270
Shares Outstanding	2,946,218
Market Cap	356,198
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	16
Country	Canada
Website	BCTXW

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCTXW's peers: BEATW, BCTX, GOVXW, IMTXW, ATNFW, RVPHW

*Chart delayed

Analyzing fundamentals for BCTXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BCTXW Fundamentals page.

Watching at BCTXW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BCTXW Technicals page.